{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T09:48:15Z","timestamp":1764841695861},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.beha.2012.04.003","type":"journal-article","created":{"date-parts":[[2012,5,23]],"date-time":"2012-05-23T19:41:31Z","timestamp":1337802091000},"page":"211-220","source":"Crossref","is-referenced-by-count":7,"title":["Autologous transplantation and management of younger patients with mantle cell lymphoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Christian H.","family":"Geisler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2012.04.003_bib1","doi-asserted-by":"crossref","unstructured":"The Non-Hodgkin\u2019s Lymphoma Classification project. A clinicopathological evaluation of the International lymphoma Study group classification of non-Hodgkin\u2019s lymphoma. Blood 1997;87: 3909\u20133918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"10.1016\/j.beha.2012.04.003_bib2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the Unites States between 1992 and 1998","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2012.04.003_bib3","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1182\/blood.V87.11.4483.bloodjournal87114483","article-title":"Mantle cell lymphoma\u2013 an entity comes of age","volume":"87","author":"Weisenburger","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.003_bib4","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapies","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2012.04.003_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.semcancer.2011.09.008","article-title":"New molecular targets in mantle cell lymphoma","volume":"21","author":"Parekh","year":"2011","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.beha.2012.04.003_bib6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.003_bib7","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.003_bib8","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood.V77.7.1587.1587","article-title":"Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation","volume":"77","author":"Philip","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.003_bib9","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.003_bib10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","article-title":"Outcome of autologous transplantation for mantle cell lymphoma: a study by the European blood and bone marrow transplant and autologous blood and marrow transplant Registries","volume":"120","author":"Vandenberghe","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2012.04.003_bib11","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose metothrexate\/cytarabine followed by stem cell transplantation: an active regimen for mantle cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.003_bib12","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.003_bib13","first-page":"1975","article-title":"Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma","volume":"10","author":"Haas","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2012.04.003_bib14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bmt.1701400","article-title":"High-dose therapy with stem-cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience","volume":"22","author":"Milpied","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2012.04.003_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","article-title":"High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission","volume":"16","author":"Freedman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.003_bib16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.bmt.1702135","article-title":"Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study","volume":"25","author":"Decaudin","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2012.04.003_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.thj.6200007","article-title":"The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients","volume":"1","author":"Dreger","year":"2000","journal-title":"Hematol J"},{"key":"10.1016\/j.beha.2012.04.003_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1034\/j.1600-0609.2003.00093.x","article-title":"Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant","volume":"71","author":"Andersen","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2012.04.003_bib19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2141.2007.06908.x","article-title":"A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma","volume":"140","author":"Evens","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2012.04.003_bib20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in\u00a0vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"issue":"Suppl. 4","key":"10.1016\/j.beha.2012.04.003_bib21","first-page":"134","article-title":"Total body irradiation (TBI) in the conditioning regimen of autologous stem cell transplantation reduces the risk of relapse of mantle cell lymphoma transplanted in partial remission: a retrospective study from the Lymphoma Working Party of the EBMT","volume":"22","author":"Rubio","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2012.04.003_bib22","first-page":"116","author":"Hermine","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.003_bib23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajh.21036","article-title":"Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond","volume":"2","author":"Zhou","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2012.04.003_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","article-title":"Phase-II trial of a transplantation regimen of Yttrium-90 ibritumomb tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma","volume":"26","author":"Krishnan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.003_bib25","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapu with in-vivo purged stem cell rescue: a non-andomized phase-2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.003_bib26","first-page":"114","article-title":"90Y-Ibritumumab Tiuexetan (Zevalin\u00ae) \u2013 BEAM\/C with autologous stem cell support as frontline therapy for advanced mantle cell lymphoma. \u2013 Preliminary results from the Third Nordic MCL phase II study (MCL3)","author":"Kolstad","year":"2009","journal-title":"Blood (ASH) Annu Meet Abstr"},{"key":"10.1016\/j.beha.2012.04.003_bib27","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1023\/A:1013578523579","article-title":"Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients","volume":"12","author":"Haioun","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2012.04.003_bib28","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.bbmt.2010.11.017","article-title":"GOELAMS. Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study","volume":"17","author":"Monjanel","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2012.04.003_bib29","first-page":"108","article-title":"90Y Ibritumomab tiuxetan (Zevalin\u00ae; 90YZ) doses Calculated to Deliver up to 1500 cGy to Critical Organs may Be Safely combined with high-dose BEAM and autotransplant in NHL","author":"Winter","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.003_bib30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3324\/haematol.10608","article-title":"Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome","volume":"92","author":"Dreger","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2012.04.003_bib31","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.bmt.1701637","article-title":"Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: the case for purging?","volume":"23","author":"Jacquy","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2012.04.003_bib32","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V90.10.4212","article-title":"Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease","volume":"90","author":"Andersen","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.003_bib33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hon.2900070505","article-title":"Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis","volume":"7","author":"Meusers","year":"1989","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2012.04.003_bib34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2012.04.003_bib35","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.003_bib36","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of event-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.003_bib37","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2008.07498.x","article-title":"High-dose Ara-C and BEAM with autograft rescue in R-CHOP responsive mantle cell lymphoma patients","volume":"144","author":"van't Veer","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2012.04.003_bib38","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.003_bib39","doi-asserted-by":"crossref","first-page":"121a","DOI":"10.1182\/blood.V110.11.387.387","article-title":"A Multi center trial of hyperCVAD+Rituxan in patients with newly diagnosed mantle cell lymphoma","volume":"110","author":"Epner","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.003_bib40","first-page":"116","article-title":"High response rates after 4 courses of R-DHAP in untreated mantle cell lymphoma (MCL) in the ongoing phase-III randomized GOELAMS and GELA LyMa Trial","author":"Le Gouill","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.003_bib41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/10428190802641979","article-title":"Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +\/\u2212 rituximab","volume":"50","author":"Eve","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2012.04.003_bib42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2012.04.003_bib43","first-page":"116","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.003_bib44","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantlecell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.003_bib45","article-title":"Detection of minimal residual disease following Induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909","author":"Liu","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2012.04.003_bib46","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.003_bib47","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.003_bib48","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2010.33.7055","article-title":"Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation","volume":"29","author":"Budde","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl. 4","key":"10.1016\/j.beha.2012.04.003_bib49","first-page":"162","article-title":"High-dose Aracytine in induction might counteract the adverse prognostic value of gene copy number alteration in autografted MCL patients. An EUMCL Network study","volume":"22","author":"Delfau-Larue","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2012.04.003_bib50","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.003_bib51","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.003_bib52","first-page":"117","article-title":"R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-Alfa: outcome of the first randomized trial for elderly patients with mantle cell lymphoma","author":"Kluin-Nelemans","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.003_bib53","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Successful preemptive treatment of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.003_bib54","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","article-title":"Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma","volume":"12","author":"Ladetto","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2012.04.003_bib55","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.seminhematol.2011.03.009","article-title":"Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go?","volume":"48","author":"Le Gouill","year":"2011","journal-title":"Semin Hematol"},{"issue":"suppl. 4","key":"10.1016\/j.beha.2012.04.003_bib56","first-page":"162","article-title":"Update of the Nordic MCL2 Trial: 10-year survival 57% following intensive immunochemotherapy and ASCT, but late relapses do occur","volume":"22","author":"Geisler","year":"2011","journal-title":"Ann Oncol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692612000308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692612000308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T19:26:07Z","timestamp":1713986767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692612000308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1521692612000308"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2012.04.003","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}